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Abstract
Tumor necrosis factor (TNF) plays a dual role in neurodegenerative diseases. Whereas TNF receptor (TNFR) 1 is
predominantly associated with neurodegeneration, TNFR2 is involved in tissue regeneration and neuroprotection.
Accordingly, the availability of TNFR2-selective agonists could allow the development of new therapeutic treatments of
neurodegenerative diseases. We constructed a soluble, human TNFR2 agonist (TNC-scTNFR2) by genetic fusion of the
trimerization domain of tenascin C to a TNFR2-selective single-chain TNF molecule, which is comprised of three TNF
domains connected by short peptide linkers. TNC-scTNFR2 specifically activated TNFR2 and possessed membrane-TNF
mimetic activity, resulting in TNFR2 signaling complex formation and activation of downstream signaling pathways.
Protection from neurodegeneration was assessed using the human dopaminergic neuronal cell line LUHMES. First we show
that TNC-scTNFR2 interfered with cell death pathways subsequent to H2O2 exposure. Protection from cell death was
dependent on TNFR2 activation of the PI3K-PKB/Akt pathway, evident from restoration of H2O2 sensitivity in the presence of
PI3K inhibitor LY294002. Second, in an in vitro model of Parkinson disease, TNC-scTNFR2 rescues neurons after induction of
cell death by 6-OHDA. Since TNFR2 is not only promoting anti-apoptotic responses but also plays an important role in tissue
regeneration, activation of TNFR2 signaling by TNC-scTNFR2 appears a promising strategy to ameliorate neurodegenerative
processes.
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Introduction
Tumor necrosis factor (TNF), plays a dominant role in the
initiation and perpetuation of chronic inflammation [1], a
condition that can lead to a variety of diseases. Blocking of TNF
signaling has been evaluated in various inflammatory diseases and
is successfully used for treatment of autoimmune diseases such as
rheumatoid arthritis, Crohn’s disease and psoriasis [2,3]. Chronic
inflammation is a common feature of neurodegenerative diseases
of the central nervous system, such as Alzheimer’s disease,
Parkinson’s disease (PD) and multiple sclerosis (MS), too [4], and
TNF signaling has been implicated as an important factor for the
onset of demyelinating diseases. However, despite promising
results in mouse models of MS, clinical trials with TNF
neutralizing reagents in MS patients failed to ameliorate the
disease and in some cases even led to disease exacerbation [5].
Since then, the dual role of TNF in the CNS has been
investigated in various mouse models, revealing significant
beneficial effects predominantly mediated by TNF receptor
(TNFR) 2, whereas TNFR1, directly and indirectly promotes
neurotoxicity [2,6]. In particular, it has been demonstrated that
TNFR2 can protect neurons against excitotoxic insults in vitro [7,8]
and promotes neuronal survival as well as oligodendrocyte
regeneration after ischemic and neurotoxic insults, respectively
[9,10]. In contrast, TNFR1 exacerbated axonal and neuronal
damage through its potent pro-inflammatory effects, which
became particularly obvious under chronic inflammatory situa-
tions [11]. Therefore, TNF remains a primary therapeutic target
for the treatment of neuroimmune diseases, but therapeutic
interference should be strictly receptor selective.
Using genetic engineering we have designed soluble human
TNFR2-selective agonists. TNFR2 selectivity has been ensured by
introducing known TNFR discriminating mutations in the TNF
molecule (D143N/A145R; [12]). We used the TNFR2-selective
mutant in the single-chain TNF format (scTNFR2), consisting of
three TNF monomers connected by short peptide linkers [13,14].
Since TNFR2 is only fully activated by membrane-bound TNF
(memTNF) but not by soluble TNF trimers [15], the trimerization
domain of tenascin C (TNC) was fused to the N-terminus of the
TNFR2-selective scTNF. This molecule (TNC-scTNFR2) exists in
a trimeric assembly of the single stranded fusion protein thus
resembling a nonameric TNF molecule, which by its increased
avidity mimics memTNF activity. In pilot studies with a prototype
of TNC-scTNFR2 it has been verified that this molecule format
allows activation of human TNFR2 without the requirement of
secondary cross-linking of TNFR2 [16].
In the current work, we describe a fully human TNC-scTNFR2
in which peptide linker sequences were reduced and overall
nucleic acid sequence was optimized for improved expression
and function. After verifying selective human TNFR2 activation
we evaluated the neuroprotective effect of TNC-scTNFR2 on
LUHMES cells, an established neuronal precursor cell line that
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has retained the potential of neuronal differentiation into a
dopaminergic phenotype [17,18,19,20].
Results
Expression and characterization of human TNC-scTNFR2
A prototype of a TNFR2-selective highly bioactive TNF variant
has been recently reported [16], comprised of the chicken TNC
trimerization domain and a TNFR2-selective TNF mutant
(D143N/A145R; [12]) in the single chain TNF format [13]. To
obtain a fully human TNF reagent we here fused the trimerization
domain of human TNC (AA 110–139) to the N-terminus of the
TNFR2-selective scTNF variant (TNC-scTNFR2), which was
further modified for improved production. Thus, peptide linkers
connecting the three TNF monomers were reduced to GGGGS
and overall codon usage was adapted for expression in
mammalian cell systems. Bioactivity of TNC-scTNFR2 was
compared to the monomeric TNFR2-selective scTNFR2 (sche-
matic overview in Fig. 1a and b).
Both scTNFR2 and TNC-scTNFR2 were expressed in
HEK293T cells and isolated by immobilized metal ion chroma-
tography (IMAC) in a single step using a N-terminal his-tag
present in the molecule. Purity was confirmed by SDS-PAGE and
Coomassie staining (Fig. 1C). Under reducing conditions the TNF
variants exhibited an apparent molecular mass of approximately
51 kDa and 54 kDa, matching the calculated molecular mass of
53.5 kDa and 56.8 kDa for scTNFR2 and TNC-scTNFR2,
respectively. Under non-reducing conditions additional bands of
110 kDa (dimer) and above 170 kDa (trimer) were observed for
TNC-scTNFR2 (Fig. 1C and D). The oligomerization state of
TNC-scTNFR2 was further characterized by size exclusion
chromatography (SEC; Fig. 1E). Both scTNFR2 and TNC-
scTNFR2 eluted as a single major peak and TNC-scTNFR2 with
a higher molecular mass than scTNFR2, indicating that the TNC
domain, as expected, causes stable oligomerization of scTNFR2
molecules. The fact that TNC-scTNFR2 elutes in a single peak
while migrating in non-reducing SDS-PAGE as dimers and
trimers is in good accordance with the finding that the TNC
trimerization domain assembles into stable trimers without
stabilization of disulfide bridges.
Receptor selectivity and bioactivity of TNC-scTNFR2
TNF receptor selectivity of scTNFR2 and TNC-scTNFR2 was
analyzed using TNFR12/2/TNFR22/2 mouse embryonic fibro-
blasts (MEF) stably expressing chimeric TNFRecd-Fasicd receptors
that bind human TNF and trigger Fas-associated signaling
pathways, e.g. apoptosis induction [21]. In contrast to human
soluble recombinant TNF (huTNF), the TNFR2-selective TNF
variants generated here induced no apoptosis in MEF TNFR1-Fas
cells (Fig. 2A), verifying that both variants had highly reduced
affinities for TNFR1 due to the mutations D143N/A145R. In
contrast, TNC-scTNFR2 induced a strong apoptotic response in
MEF TNFR2-Fas cells. Treatment with huTNF and scTNFR2
caused cell death only at high concentrations, which could be
enhanced by addition of the cross-linking TNFR2-specific
monoclonal antibody 80M2 (Fig. 2A) to similar values as obtained
for TNC-scTNFR2 alone, thus in concert mimicking the action of
memTNF [15]. Similar results were obtained using the human
Figure 1. Genetic engineering of the TNFR2-selective TNF muteins. (A,B) Schematic representation of the TNF variants used in this study. CT:
cys-tag, HT: his-tag; TNF: huTNFR2-specific (D143N/A145R) TNF module (aa 80–233); L: GGGGS-linker; TNC: trimerization domain of human tenascin C
(aa 110–139). (C) Coomassie staining and (D) immunoblot analysis of scTNFR2 (1) and TNC-scTNFR2 (2). Purified TNF variants were analyzed by 8%
SDS-PAGE under reducing (r.) or non-reducing (n.r.) conditions and either stained with Coomassie or immunoblotted with anti-his-tag antibodies.
(E) TNF muteins were analyzed by HPLC size exclusion chromatography using a BioSep-Sec-2000 column. Peak positions of relevant standard
proteins are indicated (200 kDa; 67 kDa and 29 kDa).
doi:10.1371/journal.pone.0027621.g001
Neuroregeneration by a TNFR2 Agonist
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27621
rhabdomyosarcoma cell line Kym-1 (Fig. 2B), which endogenously
expresses both TNF receptors and is highly sensitive to TNF-
induced cytotoxicity [22].
Using near to saturating concentrations (10 ng/ml), where both
scTNFR2 and TNC-scTNFR2 showed maximum bioactivity in a
long term bioassay (induction of cell death in Kym-1 cells as shown
in 2B), we further investigated the kinetics of NFkB p65 nuclear
translocation (Fig. 3). Whereas scTNFR2 stimulation only resulted
in a significant translocation after 60 minutes with 32% of the cells
showing nuclear NFkB, TNC-scTNFR2 stimulation resulted in a
rapid NFkB translocation with an apparent peak at 30 minutes
(85% NFkB+ cells), which was maintained at a high level for at
least one hour (60% NFkB+ cells), further demonstrating the
superior bioactivity of TNC-scTNFR2.
TNC-scTNFR2 induces clustering of TNFR2
To further analyze the bioactivity of TNC-scTNFR2 we used the
human TNFR2 (huTNFR2) expressing cell line R2 MEF [23]. We
recently demonstrated in these cells that upon activation of
TNFR2 by soluble TNF in combination with 80M2, the adaptor
protein TRAF2 is recruited to the receptor and the classical NFkB
pathway is activated [23]. Here we demonstrate that stimulation of
R2 MEF with TNC-scTNFR2 results in co-immunoprecipitation
of TRAF2 with TNFR2 (Fig. 4A) and activation of the classical
NFkB pathway (Fig. 4B). In addition, the PI3K-PKB/Akt
pathway was activated, as evident by the increased phosphoryla-
tion level of PKB/Akt after TNC-scTNFR2 stimulation (Fig. 4C).
The enhanced activation of NFkB (Fig. 3) suggests a more
efficient and/or faster formation of TNFR2 signaling complexes
by TNC-scTNFR2. To confirm this, we investigated the ligand-
induced recruitment of TRAF2, the essential cytosolic signal
transducer of TNFR2, to the membrane using immunofluores-
cence analysis of a TRAF2-eGFP reporter (Fig. 5). Unstimulated
Figure 2. Bioactivity and receptor selectivity of the TNF
muteins. Mouse embryonic fibroblasts (MEF) from TNFR12/2/
TNFR22/2 mice stably transfected with the chimeric receptors TNFR1-
Fas or TNFR2-Fas (A) or Kym-1 cells (B) were stimulated with wildtype
human TNF (huTNF; N), scTNFR2 (&) or TNC-scTNFR2 (m). Where
indicated, MEF TNFR2-Fas were pretreated with the ligand/receptor
stabilizing monoclonal antibody 80M2 (open symbols; 1 mg/ml; 30 min)
before TNF treatment. Cell viability was determined by crystal violet
staining after 24 hours (n = 3, shown are the mean values 6 SEM).
doi:10.1371/journal.pone.0027621.g002
Figure 3. Comparison of the NFkB translocation after stimula-
tion with scTNFR2 or TNC-scTNFR2. Kym-1 cells were stimulated
with scTNFR2 or TNC-scTNFR2 (10 ng/ml) for 10, 30 or 60 minutes. Cells
were fixed with 4% PFA, permeabilized with 0.1% Triton-X100 and
stained with anti-NFkB p65 antibodies and Alexa-Fluor546-labeled
secondary antibodies. Cell nuclei were visualized using DAPI. Shown are
representative images at point of time 30 minutes (upper panel) and
the quantification of the number of NFkB p65-positive nuclei. At least
200 cells were analyzed per condition. *p values less than 0.01 versus
untreated controls were considered to be significant (n = 2; shown are
the mean values 6 SD; bar = 20 mm).
doi:10.1371/journal.pone.0027621.g003
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R2 MEF expressing TRAF2-eGFP showed a homogenous
cytosolic distribution of the reporter. As expected [23], cross-
linking of TNFR2 by 80M2 resulted in a spotted appearance of the
TNFR2 signal at the plasma membrane, yet did not induce
colocalization with the TRAF2-eGFP signal (Fig. 5A). Similar,
stimulation with scTNFR2 alone did not result in a detectable
colocalization of the TRAF2-eGFP signal with either huTNFR2
(Fig. 5A) or scTNFR2 itself, stained with antibodies against human
TNF (huTNF; Fig. 5B) during the observation period (10 min). In
contrast, scTNFR2 in combination with 80M2 induced TNFR2
clustering and TRAF2 recruitment, apparent as a spotted
appearance of huTNFR2 (Fig. 5A) or huTNF (Fig. 5B) signal
colocalizing with TRAF2-eGFP. This finding indicates TNFR2
signaling complex formation [23]. In contrast to scTNFR2, TNC-
scTNFR2 alone was sufficient to rapidly induce TNFR2 clustering
and TRAF2 recruitment and thus efficient formation of TNFR2
signaling complexes (Fig. 5A and B). Summarizing, TNC-
scTNFR2 showed superior bioactivity compared to scTNFR2 and
was able to efficiently activate TNFR2 in distinct cell lines.
TNC-scTNFR2 preserves neurons from
superoxide-induced cell death
TNFR2 signaling has been associated with protection of
neurons against cytotoxic insults [7,8,9]. Potential neuroprotective
properties of TNC-scTNFR2 were investigated using the human
cell line LUHMES, which has been shown to display typical
biochemical and morphological features of human dopaminergic
neurons [17,18,19,20]. Differentiated LUHMES cells developed
long dendrites, formed a neural-like network and expressed typical
neuronal markers such as b-III-tubulin, a-synapsin, microtubule-
associated protein 2 and neurofilament [18,19] (data not shown).
Short hydrogen peroxide (H2O2) exposure was used to induce
cell death in vitro, simulating oxidative stress, a process that
contributes to the damage in neurodegenerative diseases in vivo. To
investigate the sensitivity of LUHMES cells to H2O2-induced cell
death, the cells were incubated for one hour with the toxic
chemical, then medium was exchanged to remove H2O2 and cells
were cultivated for additional 24 hours. LUHMES cells started to
die at H2O2 concentrations above 20 mM, with a half maximal
effective concentration (EC50) of approximately 75 mM (Fig. 6A).
Addition of TNC-scTNFR2 one hour after exposure to a toxic
concentration of H2O2, counteracted the H2O2-triggered cell
death pathway such that nearly 80% of the cells survived the
treatment, compared to 30% survival without TNC-scTNFR2
(Fig. 6B).
To investigate the protective effect of TNC-scTNFR2 in detail,
LUHMES cells were fixed two or four hours after starting the
H2O2-treatment and the b-III-tubulin content (Fig. 6C) as well as
cell number (Fig. 6D) were determined by immunofluorescence
analyses. Already two hours after H2O2 exposure, a significant
Figure 4. TNC-scTNFR2 induces TNFR2 signaling in R2 MEF. (A–C) R2 MEF were stimulated with TNC-scTNFR2 (20 ng/ml) for the indicated
times. (A) TNFR2 was immunoprecipitated using MR2-1 antibodies and protein G agarose. The precipitates were analyzed by immunoblot analysis
using anti-huTNFR2 (HP9003) and anti-TRAF2 antibodies (NB = non-bound; B = bound). (B) Localization of NFkB p65 was visualized via
immunofluorescence microscopy as shown in the upper panel and the number of nuclei showing NFkB translocation was quantified. At least
200 cells per experiment were analyzed (n = 3; shown are the mean values 6 SEM of percent NFkB positive nuclei; bar = 20 mm). (C) Phospho-Akt
(Ser473) levels in cell lysates were analyzed using immunoblot analysis. Akt was used as a loading control. Representative blot and bar graph show
the quantification of the phospho-Akt (Ser473) band. *p values less than 0.05 versus untreated cells were considered to be significant (n = 3; shown
are the mean values 6 SEM).
doi:10.1371/journal.pone.0027621.g004
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decrease in the number of cells was noted, which was further
enhanced after four hours. In contrast, no significant loss of cells
was observed at two and four hours in the samples treated with
TNC-scTNFR2 one hour after H2O2 exposure. The rapid H2O2-
induced cell death is at least partially due to apoptosis induction, as
revealed from TUNEL-staining of exposed cells (Fig. 6E). A
reduced amount of TUNEL-positive cells after regeneration in
presence of TNC-scTNFR2 further indicates that TNFR2
signaling rapidly interferes with the H2O2-induced apoptotic
signal pathways.
TNC-scTNFR2-mediated protection from superoxide
induced cell death is dependent on PI3K-PKB/Akt
signaling
PKB/Akt exerts anti-apoptotic effects [24] and mediates cell
protection in neurodegenerative diseases [25,26,27]. Furthermore,
preconditioning via TNFR2-signaling spared primary neurons
from glutamate-induced excitotoxicity in vitro in a PI3K-PKB/Akt-
dependent manner [7,8]. In accordance with these data, we could
show that the protective effect mediated by TNC-scTNFR2 is
dependent on PKB/Akt activity. First, whereas transient blocking of
PI3K for one hour with the specific inhibitor LY294002 did not
influence neuronal viability, persistent blocking of PI3K activity
resulted in a dramatic decrease in cell viability after 24 hours of
otherwise untreated neuronal cells (Fig. 7A), verifying the general
importance of PI3K-PKB/Akt signaling for neuronal cell survival
[18]. Second, upon oxidative stress already a transient inhibition of
PI3K drastically affected protection by TNFR2 stimulation, as evident
from reduced cell viability after 24 hours (Fig. 7B) and the elevated
number of TUNEL-positive cells one hour post TNC-scTNFR2
treatment (Fig. 7C). This further demonstrates that activation of the
PI3K-PKB/Akt pathway via TNFR2 results in anti-apoptotic
signaling, thereby preventing the cell death induced by H2O2.
TNC-scTNFR2 rescues neurons from catecholaminergic
cell death
LUHMES cells differentiate into neurons with a dopaminergic
phenotype [18]. The neurotoxin 6-hydroxydopamine (6-OHDA)
Figure 5. TNC-scTNFR2 induces formation of TNFR2 signaling complexes. (A,B) R2 MEF were transfected with pTRAF2-eGFP. After 24 hours,
cells were incubated with or without 80M2 (1 mg/ml) for 5 minutes on ice and subsequently incubated with scTNFR2 or TNC-scTNFR2 (10 ng/ml) for
10 minutes at 37uC. Then cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100 and localization of huTNFR2 (A) or huTNF (B) was
detected with specific antibodies and Alexa-Fluor546-labeled secondary antibodies. Cell nuclei were visualized using DAPI. Pictures are optical
sections obtained by confocal fluorescence microscopy (bar = 10 mm). White arrows indicate areas of colocalization.
doi:10.1371/journal.pone.0027621.g005
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is widely used as an oxidative stress in vitro model, which has
relevance for PD. 6-OHDA generates free radicals and selectively
induces cell death in catecholamine-containing neurons [28].
LUHMES cells were sensitive towards 6-OHDA-induced cell
death with an EC50 of approximately 5 mM (Fig. 8A). Treatment
of LUHMES cells with TNC-scTNFR2 one or two hours after
exposure to a toxic concentration of 6-OHDA, counteracted the
cell death pathway such that more than 50% of the cells survived
the treatment, compared to 20% survival without TNC-scTNFR2
(Fig. 8B), further demonstrating the protective role of TNFR2
activation in oxidative stress-induced cell death.
Discussion
Signaling via TNFR2 has been implicated in protection and
regeneration of tissues, such as pancreas, liver, heart and brain [6].
Accordingly, TNF variants selectively activating TNFR2 could be
a useful therapeutic regimen in a variety of diseases, including
heart failure, autoimmune and neurodegenerative diseases.
Towards this aim, here we describe a human TNFR2-selective
TNF ligand with memTNF-mimetic activity (TNC-scTNFR2) that
rescues differentiated neurons from cell death post insultem, i.e.
under conditions that reflect the time span of a potential
therapeutic intervention, for example to limit ischemic lesions
after stroke.
Soluble TNF is a strong mediator of inflammation, predomi-
nantly through TNFR1, which is efficiently activated by the
membrane-bound as well as the soluble form of TNF in the
picomolar range [15]. Whereas TNFR2 binds soluble TNF as well
as memTNF, it is only fully activated by the latter [15]. Therefore,
potential TNFR2-specific therapeutics have to comply with two
basic requirements: mimicry of memTNF function and receptor
Figure 6. TNC-scTNFR2 induces neuroregeneration after H2O2-induced oxidative stress. (A) Differentiated LUHMES cells were incubated
with different concentrations of hydrogen peroxide (H2O2) for one hour. Then cells were washed with medium und cultivated for additional 24 hours.
Cell viability was measured using the MTT assay (n = 3; shown are the mean values of triplicate determinations 6 SEM). (B–E) LUHMES cells were
stimulated with H2O2 (100 mM). After one hour the cells were washed with medium und regenerated for the indicated time intervals in medium with
or without TNC-scTNFR2 (100 ng/ml). (B) LUHMES cells were regenerated for 24 hours and cell viability was measured using the MTT assay (n = 3,
shown are the mean values6 SEM). (C) Cells were regenerated for one or three hours, fixed with 4%PFA, permeabilized with 0.1% Triton-X100 and b-
III-tubulin was detected with specific antibodies. Cell nuclei were visualized using DAPI. Pictures are projections of eight optical sections (0.4 mm;
bar = 50 mm). (D) Number of cells was determined by counting the nuclei (DAPI staining). (E) Cells were regenerated for one hour and apoptotic cells
were identified by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-FITC nick end labeling (TUNEL). (D,E) At least 10 different image
sections containing a minimum of 500 cells were used to determine the number of total and TUNEL-positive cells. *p values less than 0.05 (** p-value
less than 0.001) were considered to be significant (n = 2, shown are the mean values 6 SD).
doi:10.1371/journal.pone.0027621.g006
Neuroregeneration by a TNFR2 Agonist
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27621
selectivity in order to avoid dose limiting severe TNFR1-related
inflammatory responses. Fusion of the trimerization domain of
tenascin C to a TNFR2-selective scTNF was shown in a previous
study to exert memTNF-like activity [16]. We generated a fully
human, optimized version of this fusion protein suitable to be
further developed into a therapeutic.
The HPLC-SEC and SDS-PAGE data indicate that for
scTNFR2 the majority of the molecules were present in monomeric
form, i.e. resembling a soluble trimeric TNF, whereas the TNC-
scTNFR2 assembled into functional multimers, most likely trimers,
thus resembling a nonameric TNF molecule. The introduced
double mutation D143N/A145R leads to a complete loss of
binding to TNFR1 [12]. Therefore, as demonstrated in an
apoptosis assay with a cell line selectively expressing TNFR1 (MEF
TNFR1-Fas), TNC-scTNFR2 did not activate TNFR1. In
contrast, TNC-scTNFR2 efficiently activated TNFR2, indicating
that the oligomeric TNF mutein is able to mimic memTNF. As a
consequence, TNC-scTNFR2 efficiently induced nuclear translo-
cation of NFkB p65 in Kym-1 cells within 30 minutes, whereas
stimulation with scTNFR2 only resulted in a marginal transloca-
tion after 30 minutes and a partial and delayed response at
60 minutes in Kym-1 cells. In these cells, this weak and late signal
seemed to be strong enough to induce endogenous expression and
secretion of TNF, which in an autocrine manner activated TNFR1
and subsequently the apoptotic signaling-cascade leading to Kym-
1 cell death (Fig. 2C), as shown previously [22,29].
Receptors of the TNF family are activated by ligand-mediated
oligomerization [30] and efficient signal initiation requires the
formation of larger ligand/receptor complexes [21,31]. In
previous studies, the initiation of cluster formation of TNFR2
was found to be dependent on exogenous cross-linking of the
ligand-receptor complexes and correlated with the particular
signaling strength [21]. Using the recently introduced huTNFR2-
expressing cell line R2 MEF [23], the superior bioactivity of the
multimeric TNC-scTNFR2 was further evident from rapid
formation of TNFR2 signaling complexes, which can be readily
visualized by fluorescence microscopy of TRAF2 recruitment.
Summarizing, the soluble TNC-scTNFR2 ligand mimics
memTNF-like activation of TNFR2 and can be used to selectively
induce TNFR2 signaling in vitro and in vivo.
Parkinson’s disease is a neurological disorder, which is
characterized by the loss of dopamine-producing neurons in the
substantia nigra causing reduced dopamine levels in the striatum
[32]. This disease [33], like a variety of other neurodegenerative
diseases, including Alzheimer’s disease [34], amyotrophic lateral
sclerosis [33] and conditions such as ischemia and excitotoxicity
[35], has been associated with mitochondrial dysfunction and
oxidative damage mediated by excessive production and exposure
of cells to reactive oxygen species (ROS) resulting in neuronal
death [36]. Oxidative stress can be simulated in vitro by brief
exposure of cultured neurons to H2O2, resulting in the induction
of cell death via the mitochondrial apoptosis pathway [37,38]. In
addition, neurotoxins, such as 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) or 6-OHDA mimic many of the hallmark
characteristics of PD and are widely used as an oxidative stress
model for PD [39,40].
Preconditioning cells via TNFR2 signaling protected primary
cortical neurons from excitotoxic cell death in an NFkB-
dependent manner [7,8]. In contrast, we activated TNFR2 by
TNC-scTNFR2 subsequent to the toxic stimulus. Interestingly,
under these conditions, simulating a therapeutic intervention, a
strongly increased survival was noted, too, indicating that TNFR2
signaling can interfere with an already activated cell death
program and promote cell survival.
Several pathways activated by TNFR2 mediate protective or
regenerative responses. In particular, PKB/Akt-dependent activa-
tion of NFkB induces expression of anti-apoptotic and/or
neurotrophic factors [7,41]. In addition, PKB/Akt signaling
directly exerts anti-apoptotic effects [24] and is involved in
mediating cell protection in neurodegenerative diseases [25,26,27].
Since TNFR2 activation by TNC-scTNFR2 subsequent to the
toxic exposure to H2O2 resulted in a fast protective response in a
Figure 7. TNC-scTNFR2-mediated neuroregeneration is depen-
dent on PI3K-PKB/Akt signaling. (A) LUHMES cells were stimulated
with LY294002 (25 mM) for either 24 hours or for 1 hour. If stimulated
for 1 hour, medium was exchanged to differentiation medium and cells
were cultivated for further 23 hours. Cell viability was measured using
the MTT assay (n = 3; shown are the mean values6 SEM). (B,C) LUHMES
cells were stimulated with hydrogen peroxide (H2O2; 100 mM) with or
without LY294002 (25 mM). After one hour the cells were washed with
medium und regenerated in medium with or without TNC-scTNFR2
(100 ng/ml). (B) Cells were incubated for 24 hours and cell viability was
measured using the MTT assay (n = 3, shown are the mean values 6
SEM). (C) Cells were regenerated for one hour, fixed with 4% PFA and
apoptotic cells were identified by terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP-FITC nick end labeling (TUNEL). At least 5 different
image sections containing a minimum of 250 cells were used to
determine the number of total and TUNEL-positive cells (n = 3, shown
are the mean values6 SEM). **p values less than 0.001 were considered
to be significant.
doi:10.1371/journal.pone.0027621.g007
Neuroregeneration by a TNFR2 Agonist
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27621
PKB/Akt-dependent manner, we assume that the protective effect
is not dependent on de novo gene expression. Indeed, PKB/Akt has
been shown to interfere with early apoptotic signals [42] and thus
could mediate protection by directly interacting with components
involved in the apoptotic signal pathway.
The molecular mechanisms of PKB/Akt-mediated survival
from H2O2-induced toxicity in the neuronal cells studied here are
not known yet. However, several components of the apoptotic
machinery share the PKB/Akt consensus phosphorylation se-
quence (RXRXXS/T), e.g. pro-death components such as Bad,
caspase-9 and caspase-8 or pro-survival factors like Bcl-2, cIAP
and xIAP [42]. PKB/Akt therefore could regulate apoptosis by
either inhibiting cell death or promoting cell survival. In
particular, phosphorylation of Bad by PKB/Akt induces the
dissociation of Bad from Bcl-XL, which then can promote cell
survival. In addition, PKB/Akt was reported to directly block cell
death after mitochondrial cytochrome C release, e.g. by
phosphorylating caspase-9 at serine 196 [43] thereby inactivating
the caspase. PKB/Akt therefore could potentially also interfere
with the apoptotic pathway even at this rather late stage.
The mechanisms of the TNFR2-mediated protection from 6-
OHDA-induced cell death are not characterized yet. However,
Jorda´n et al. [44] present evidence that Bcl-XL seems to prevent
mitochondrial multiple conductance channel opening, cytochrome
c release and caspase-3 like activity following 6-OHDA treatment.
Therefore similar mechanisms could contribute to the protection
of TNC-scTNFR2 against 6-OHDA-induced cell death as
described for protection against H2O2-induced cell death, e.g
activation of Bcl-XL through phosphorylation of Bad.
In conclusion, we constructed a human TNFR2-selective TNF
ligand possessing memTNF-mimetic activity and show that this
molecule can rescue differentiated neurons from cell death
subsequent to a toxic exposure, i.e. under conditions that reflect
the time span of a potential therapeutic intervention. Our data,
together with clear evidence that TNFR2 signaling promotes tissue
regeneration in several organs [6,10], indicate that selective
activation of TNFR2 signaling may be a promising approach to
treat various diseases, including autoimmune and neurodegener-
ative diseases. Being the first fully human TNFR2 agonist, TNC-
scTNFR2 is suitable not only for further studies on the protective
and regenerative mechanisms of TNFR2 signaling in different
disease models but represents a prototype of a TNFR2-selective
therapeutic which is in principle applicable in man as a novel
therapeutic approach to promote tissue homeostasis and regener-
ation.
Materials and Methods
Antibodies and chemicals
The TNFR2 specific antibody 80M2 has been described [15].
LY294002 and the antibodies against NFkB p65, TRAF2, Akt
and phospho Akt (Ser473) were from Cell Signaling Technology
(Boston, MA). The antibody anti-6-his was from Biovision (San
Francisco, CA), the antibodies against huTNFR2 (HP9003; MR2-
1) were from Hbt (Uden, The Netherlands), the antibody against
huTNF (AF-210-NA) was from R&D Systems (Wiesbaden,
Germany) and the antibody against b-III-tubulin was purchased
from Acris Antibodies (Hiddenhausen, Germany). Secondary
antibodies coupled to horseradish peroxidase (HRP) and Alexa-
Fluor488 or Alexa-Fluor546 were from Jackson ImmunoResearch
(Suffolk, UK) and Invitrogen (Karlsruhe, Germany), respectively.
DAPI, MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl tetrazoli-
um bromide), 6-hydroxydopamine (6-OHDA) and H2O2 (hydro-
gen peroxide) were from Sigma-Aldrich (Steinheim, Germany). All
other chemicals were of analytical grade.
Cloning of scTNFR2 and TNC-scTNFR2
The TNFR2-selective scTNFR2 (D143N/A145R) and the
human tenascin C (TNC) domain (aa 110–139) were synthesized
with optimized eukaryotic codon usage (Geneart, Regensburg,
Germany). The sequence of scTNFR2 was subcloned in frame into
the expression vector pSecTag A (Invitrogen) containing an IgG
secretion signal. Then TNC-scTNFR2 was generated by cloning of
the TNC domain sequence to the N-terminal end of the scTNFR2
construct. All vector sequences were verified by sequencing.
Cell culture
Immortalized mouse fibroblasts generated from TNFR12/2/
TNFR22/2 mice and stably transfected with human TNFR1-Fas
(MEF TNFR1-Fas) or TNFR2-Fas (MEF TNFR2-Fas) [21] or
with human TNFR2 (R2 MEF) [23] have been described
elsewhere. HEK293T cells and mouse fibroblasts were grown in
RPMI1640 medium (Invitrogen) supplemented with 5% (v/v)
heat-inactivated FCS (PAN Biotech, Aidenbach, Germany) and
100units/ml penicillin and 100 mg/ml streptomycin (Invitrogen).
Kym-1 cells were cultivated in RPMI1640 medium supplemented
Figure 8. TNC-scTNFR2 protects neurons against catecholaminergic cell death. (A) Differentiated LUHMES cells were incubated with
different concentrations of 6-hydroxydopamine (6-OHDA) for 20 hours. Cell viability was measured using the MTT assay (n = 3; shown are the mean
values of triplicate determinations6 SEM). (B) LUHMES cells were stimulated with 6-OHDA (32 mM). Cells were stimulated with TNC-scTNFR2 (100 ng/
ml) one, two or four hours after 6-OHDA addition and incubated for a total time period of 20 hours. Cell viability was measured using the MTT assay
(n = 3, shown are the mean values 6 SEM). *p values less than 0.05 (** p-value less than 0.001) were considered to be significant.
doi:10.1371/journal.pone.0027621.g008
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with 10% (v/v) heat-inactivated FCS and penicillin/streptomycin.
LUHMES cells were cultivated according to Schildknecht et al.
[19].
Production of scTNFR2 and TNC-scTNFR2
HEK293T cells were transfected with scTNFR2 or TNC-
scTNFR2 expression constructs, using lipofectamine 2000 (Invitro-
gen). Stable cells were selected with Zeocin (Invitrogen). For
protein production, cells were expanded in T175 culture flasks.
When grown to 90% confluence, cells were cultivated for a total of
8 days with Opti-MEM (Invitrogen, USA). Medium was changed
after 2 days. Supernatant was centrifuged (720g; five minutes) and
stored at 4uC. TNF variants were purified by immobilized metal
ion chromatography (IMAC). For this purpose, supernatant was
loaded onto a column containing Ni-NTA agarose (Qiagen,
Hilden, Germany) and unbound proteins were washed away using
IMAC wash buffer (50 mM sodium-phosphate-buffer, 10–30 mM
imidazole). Bound proteins were eluted with IMAC elution buffer
(50 mM sodium-phosphate-buffer, 100 mM imidazole) in frac-
tions of 1 ml. The purity of the protein in the eluted fractions was
analyzed by SDS-PAGE and pure fractions were pooled and
dialyzed (cut-off 4–6 kDa, Roth) against PBS overnight at 4uC.
Protein concentration was determined by measuring the absor-
bance at 280 nm.
SDS-PAGE and Immunoblot
Cells were lysed in homogenization buffer (10 mM HEPES
pH 7.5, 1.5 mM MgCl2, 1.5 mM KCl, 1% NP-40, 0.2 mM
PMSF, 20 mM ß-glycerophosphate and 100 mM Na3VO4) at 4uC
for 30 min. Lysates were centrifuged (2 min at 9600 g) and protein
concentration of supernatants were determined using the BCA
method (Pierce, Bonn, Germany). 20 mg total protein or 2 mg
(SDS-PAGE) and 1 mg (immunoblot) respectively of the TNF
muteins were denatured in Laemmli buffer and resolved by 8%
SDS-PAGE (100 V; 90 minutes). For Coomassie staining of
proteins the gel was incubated in Coomassie staining solution for
60 minutes at room temperature and destained. For immunoblot
analyses the proteins were transferred onto nitrocellulose mem-
branes (semidry blot; 1.5 mA/cm2 gel for 90 minutes). Non-
specific protein binding was blocked with 5% skimmed milk
powder solution in PBS/0.1% Tween20 for 30 minutes at room
temperature and the membrane was incubated overnight at 4uC
using specific antibodies. After incubation with anti-rabbit HRP-
conjugated secondary antibodies for 90 minutes at room temper-
ature the signals were detected by enhanced chemiluminescence
(Super Signal, Pierce, Rockford, IL).
Immunoprecipitation
Approximately 56106 R2 MEF were seeded in T75 cell culture
flask (Greiner) and cultivated overnight. Cells were stimulated as
indicated and homogenized with 200 ml IP lysis buffer (10 mM
TRIS pH 7.4, 100 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.5%
Triton X-100, 0.5% NP-40, 100 mM Na3VO4, 0.2 mM PMSF,
20 mM ß-glycero-phosphate, Roche complete protease inhibitor
cocktail) for 30 minutes on ice. The lysate was centrifuged
(2 minutes; 9600g; 4uC) and the supernatant was incubated with
5 mg TNFR2-specific antibody MR2-1 (Hbt) for 2 hours at 4uC.
The immunocomplexes were precipitated with protein G agarose
(75 ml; Pierce) for two hours at 4uC. The precipitates were washed
four times with IP washing buffer (10 mM TRIS pH 7.4, 100 mM
KCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40) and dissolved in
100 ml PBS, supplemented with Laemmli buffer. To elute bound
proteins, the precipitates were boiled for five minutes at 95uC.
30 ml of the eluted proteins were separated by SDS-PAGE and
analyzed by immunoblot analysis.
HPLC
The oligomerization state of the TNF variants under native
conditions was analyzed by HPLC-SEC. 50 ml sample (0.1 to
0.5 mg/ml) was applied to a BioSep-SEC-S2000 7.86300 column
(Phenomenex, Aschaffenburg, Germany) equilibrated with PBS
and eluted at a flow rate of 0.5 ml/min. For determining the size
of recombinant proteins, standard proteins (29 kDa, carbonic
anhydrase; 67 kDa, bovine serum albumin (BSA); 200 kDa, b-
amylase; 443 kDa, apoferritin; 669 kDa, thyroglobulin) were run
under the same conditions.
Cell survival assays
Crystal violet. Mouse fibroblasts or Kym-1 cells (16104
cells/well) were grown in 96-well flat bottom cell culture plates
overnight. If indicated, the cells were stimulated with 80M2 (1 mg/
ml) for 30 minutes. Then the cells were incubated with different
concentrations of TNF variants for 24 hours at 37uC. The cells
were washed with PBS and incubated with crystal violet (20%
methanol; 0.5% crystal violet) for 20 minutes to stain viable cells.
The dye was washed away under rinsing water and the cells were
air-dried. Crystal violet was resolved with methanol and the
optical density at 550 nm was determined. Each sample was
analyzed in triplicates and data were analyzed using the software
Microsoft Excel and GraphPad Prism 4.
MTT. Fully differentiated LUHMES cells cultivated in 96-
well plates were stimulated with H2O2 with or without LY294002
(25 mM). After one hour cells were washed with medium and
regenerated in medium with or without TNC-scTNFR2 (100 ng/
ml). After 24 hours, the medium was removed carefully and 60 ml
MTT solution (1,25 mg/ml) diluted 1:6 in DMEM (1% FCS) was
added. Cells were incubated for 90 minutes at 37uC. Then 150 ml
acidic isopropanol was added and cells were dissolved. Absorbance
was measured at 550 nm.
Differentiated LUHMES cells were stimulated with 6-OHDA.
After 1, 2 or 4 hours TNC-scTNFR2 (100 ng/ml) was added and
cells were cultured for a total time of 20 hours. Cell viability was
determined as described above. Each sample was analyzed in
triplicates and cell viability was calculated using the software
Microsoft Excel and GraphPad Prism 4.
TUNEL. Fully differentiated LUHMES cells cultivated on
cover slips were stimulated with H2O2. After one hour, the cells
were washed with medium and regenerated for the indicated times
in medium with or without TNC-scTNFR2 (100 ng/ml). At point
in time zero, the cells were washed with PBS, fixed with PBS/
4%PFA for 20 minutes at 37uC and permeabilized with PBS/
0.1% TritonX-100 for five minutes at room temperature. Labeling
with the TUNEL reaction mix was performed due to the
recommendations of the manufacturer (Roche Applied Science,
Mannheim, Germany). Coverslips were mounted with
Fluoromount G (Southern Biotech, Birmingham, AL). The
fluorescence was analyzed by wide-field fluorescence microscopy
(CellObserver, Carl Zeiss).
Fluorescence microscopy
For immunofluorescence analyses LUHMES cells were culti-
vated on PLO-fibronectin-coated cover slips and differentiated for
72 hours as described in [19]. R2 MEF and Kym-1 cells (36104
cells/well) were cultivated overnight on Lab-Tek 8-well chamber
glass slides (Thermo, Schwerte, Germany) coated with 10 mg/ml
poly-D-lysine (Sigma) for one hour at 37uC. If indicated in the
legend, R2 MEFs were transiently transfected with pTRAF2-
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eGFP expression constructs using lipofectamine 2000 (Invitrogen)
according to the manufacturer’s recommendations. The next day,
cells were stimulated with TNF muteins, as indicated, and fixed
with PBS/4% PFA for 30 minutes on ice at point in time zero.
Then cells were permeabilized with PBS/0.1% Triton-X100 for
10 minutes at room temperature. Unspecific binding sites were
blocked with PBS/4% BSA for 30 min and cells were subse-
quently incubated with primary antibodies for 60 min followed by
the incubation with appropriate fluorescence-labeled secondary
antibodies for 45 min in PBS/2% BSA. After staining the nuclei
with DAPI the cells were mounted with Fluoromount G (Southern
Biotech). The labeled cells were analyzed by wide-field fluores-
cence microscopy (CellObserver with Colibri LED modules, Carl
Zeiss, Jena, Germany) or by confocal laser scanning microscopy
(LSM710, Carl Zeiss). The analysis of the obtained data and
imaging was performed with the AxioVision Rel 4.7 (Carl Zeiss;
CellObserver) or ZenLightEdition (Carl Zeiss; LSM710) software.
Isotype or secondary antibodies control stainings were used to
determine background fluorescence and to adjust the intensity of
specific stainings.
Quantification and statistical analysis
To quantify protein amounts, detected by immunoblot blot
analysis, films were scanned and integrated optical densities were
calculated using ImageJ. Integrated optical densities were
corrected for background intensities. For quantification of nuclear
translocation of NFkB in immunofluorescence experiments, the
number of cells with NFkB positive nuclei of at least 200 cells per
experiment and condition was determined.
Normal distribution was analyzed by Shapiro-Wilk normally
test. Statistical analysis was performed by the Tukey range test.
P,0.05 was considered significant.
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